Abstract：
UNASSIGNED: The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a recurrence following prior treatment with curative intent. This is Part II of a three-part series focusing on treatment delivery for non-metastatic biochemical recurrence (BCR) after primary radical prostatectomy (RP). Please refer to Part I for discussion of treatment decision-making and Part III for discussion of evaluation and management of recurrence after radiotherapy (RT) and focal therapy, regional recurrence, and oligometastasis.
UNASSIGNED: The systematic review that informs this Guideline was based on searches in Ovid MEDLINE (1946 to July 21, 2022), Cochrane Central Register of Controlled Trials (through August 2022), and Cochrane Database of Systematic Reviews (through August 2022). Update searches were conducted on July 26, 2023. Searches were supplemented by reviewing electronic database reference lists of relevant articles.
UNASSIGNED: In a collaborative effort between AUA, ASTRO, and SUO, the Salvage Therapy for Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance for the care of patients who experience BCR after initial definitive local therapy for clinically localized disease.
UNASSIGNED: Optimizing and personalizing the approach to salvage therapy remains an ongoing area of work in the field of genitourinary oncology and represents an area of research and clinical care that requires well-coordinated, multi-disciplinary efforts.
UNASSIGNED: The systematic review that informs this Guideline was based on searches in Ovid MEDLINE (1946 to July 21, 2022), Cochrane Central Register of Controlled Trials (through August 2022), and Cochrane Database of Systematic Reviews (through August 2022). Update searches were conducted on July 26, 2023. Searches were supplemented by reviewing electronic database reference lists of relevant articles.
UNASSIGNED: In a collaborative effort between AUA, ASTRO, and SUO, the Salvage Therapy for Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance for the care of patients who experience BCR after initial definitive local therapy for clinically localized disease.
UNASSIGNED: Optimizing and personalizing the approach to salvage therapy remains an ongoing area of work in the field of genitourinary oncology and represents an area of research and clinical care that requires well-coordinated, multi-disciplinary efforts.
摘要：
本文提供的概述涵盖了关于复发性前列腺癌的挽救治疗的建议，旨在促进护理决策并帮助临床医生照顾在具有治愈意图的先前治疗后经历复发的患者。这是一个由三部分组成的系列的第二部分，重点是原发性根治性前列腺切除术（RP）后非转移性生化复发（BCR）的治疗。有关治疗决策的讨论，请参阅第一部分，有关放疗（RT）和局部治疗后复发的评估和管理的讨论，请参阅第三部分。区域性复发，和寡转移。
■通知本指南的系统评价是基于OvidMEDLINE中的搜索（1946年至2022年7月21日），Cochrane中央受控试验登记册（至2022年8月），和Cochrane系统评价数据库(至2022年8月)。更新搜索于2023年7月26日进行。通过审查相关文章的电子数据库参考清单来补充搜索。
■在AUA之间的合作努力中，ASTRO,而SUO,前列腺癌挽救治疗小组制定了以证据和共识为基础的指南声明,为在临床局部疾病的初步确定局部治疗后出现BCR的患者的护理提供指导.
■优化和个性化抢救治疗方法仍然是泌尿生殖系统肿瘤学领域正在进行的工作领域，代表了需要良好协调的研究和临床护理领域，多学科的努力。
■通知本指南的系统评价是基于OvidMEDLINE中的搜索（1946年至2022年7月21日），Cochrane中央受控试验登记册（至2022年8月），和Cochrane系统评价数据库(至2022年8月)。更新搜索于2023年7月26日进行。通过审查相关文章的电子数据库参考清单来补充搜索。
■在AUA之间的合作努力中，ASTRO,而SUO,前列腺癌挽救治疗小组制定了以证据和共识为基础的指南声明,为在临床局部疾病的初步确定局部治疗后出现BCR的患者的护理提供指导.
■优化和个性化抢救治疗方法仍然是泌尿生殖系统肿瘤学领域正在进行的工作领域，代表了需要良好协调的研究和临床护理领域，多学科的努力。
